Report of Foreign Issuer (6-k)
March 22 2017 - 7:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 or 15d-16
UNDER
THE SECURITIES EXCHANGE ACT
of 1934
For the Month of March 2017
001-37521
(Commission File Number)
INTEC PHARMA LTD.
(Translation of registrant’s name into
English)
12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel
(+972) (2) 586-4657
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F
☒
Form
40-F
☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________
EXPLANATORY
NOTE
On
March 22, 2017, Intec Pharma Ltd., issued a press release titled “Intec Pharma Initiates Phase I Trial of Accordion Pill
for Cannabinoid Therapies.”
Copy
of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Zeev Weiss
|
|
|
Name: Zeev Weiss
|
|
|
Title: Chief Executive Officer
|
Date: March 22, 2017
EXHIBIT
INDEX
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated March 22, 2017
|
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2023 to Sep 2024